Navigation Links
Angina drug potentially useful against heart rhythm disorders
Date:3/31/2008

patients with angina, severe chest pain caused by inadequate blood flow to the heart, are also more likely to experience arrhythmias. Researchers got a clue that ranolazine, approved in January 2006, might influence QTc during its angina clinical trials, where it was found to have electrophysiological side effects.

Past studies have shown that people with angina are also at risk for rhythm disorders, said Arthur Moss, M.D., professor of Medicine in the Department of Medicine at the University of Rochester Medical Center and lead author on the ranolazine abstract. Our study found that we may be able to treat two conditions for the price of one with this drug. Specifically, Ranolazine shortens the QTc interval and improves myocardial relaxation in patients with the LQT3 mutation.

In a carefully controlled setting, and with informed consent, researchers gave five patients with the LQT3 mutation an 8-hour intravenous infusion of ranolazine, with ECG and ECHO evaluation before, during, and after treatment. Over the infusion period, the mean reduction in QTc from baseline was 26 +/- 3ms (p<0.0001). This represents about a five percent reduction in the QTc duration, researchers said.

In addition, researchers observed a significant 13 percent shortening in left ventricular isovolumic relaxation time and a significant 25 percent increase in mitral E-wave velocity during the infusion. Both are measures of how well an important chamber of the heart, the left ventricle, relaxes after each heartbeat, enabling it to fill with blood before the next contraction. Past studies have shown that the ability of the ventricle to relax is lessened, not just in Long QT, but also in more common post-heart attack arrhythmias and in conditions including hypertension, coronary artery disease and diabetes. Researchers said that ranolazine was the first treatment to bring about improved ventricular relaxation. No adverse effects of ranolazine were observed.

<
'/>"/>
Contact: Greg Williams
Greg_Williams@urmc.rochester.edu
University of Rochester Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2 3

Related medicine news :

1. Trial to Test Gene Therapy for Angina in Women
2. Docs Debate Drugs vs. Surgery for Angina
3. Doctors Debate Drugs vs. Surgery for Angina
4. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
5. Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction
6. Cone-Beam CT faster, potentially more accurate than conventional mammography
7. Hot liquids release potentially harmful chemicals in polycarbonate plastic bottles
8. Heating Plastic Bottles Releases Potentially Harmful Chemical
9. ASAM Calls for Care in the Use of, and the Prescribing of, Potentially Addictive Substances
10. Cerimon to Conduct a Proof of Concept Study for Basiliximab for Noninfectious Uveitis, a Potentially Sight-Threatening Inflammation of the Eye
11. Regenstrief Institute tapped by CDC to combat potentially catastrophic disease outbreaks
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 2Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 3Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 4Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 2Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 4Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 5Crisis in Aging 3A Disability and Alzheimer 26apos 3Bs 3A Lack of Caregivers Threatens South Florida Seniors 26apos 3B Ability to Stay Home 58441 1Crisis in Aging 3A Disability and Alzheimer 26apos 3Bs 3A Lack of Caregivers Threatens South Florida Seniors 26apos 3B Ability to Stay Home 58441 2Crisis in Aging 3A Disability and Alzheimer 26apos 3Bs 3A Lack of Caregivers Threatens South Florida Seniors 26apos 3B Ability to Stay Home 58441 3Crisis in Aging 3A Disability and Alzheimer 26apos 3Bs 3A Lack of Caregivers Threatens South Florida Seniors 26apos 3B Ability to Stay Home 58441 4Boot Camp for New Dads to Hold Master Coach Certification Training in Denver October 2 3 2009 58439 1Boot Camp for New Dads to Hold Master Coach Certification Training in Denver October 2 3 2009 58439 2Boot Camp for New Dads to Hold Master Coach Certification Training in Denver October 2 3 2009 58439 3Paul Marks prize recognizes 3 young cancer researchers 58437 1Paul Marks prize recognizes 3 young cancer researchers 58437 2Paul Marks prize recognizes 3 young cancer researchers 58437 3Paul Marks prize recognizes 3 young cancer researchers 58437 4Paul Marks prize recognizes 3 young cancer researchers 58437 5